stockrow
Friday 6 November 2026
Export FLGT’s income statement to Excel — free account
Fulgent Genetics, Inc.
FLGT Healthcare Diagnostics & Research
Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024.
- Revenue
- +7.54%
- EPS
- −128.6%
- Free cash flow
- +2,058.7%
Quarter to September 2026, against a year earlier
22.39
3.73
+19.99%
Follow FLGT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.84 | 1.77 | 1.53 | 2.51 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
5.58 | (24.19) | 69.19 | (10.35) | |
P/B ratio |
0.62 | 0.58 | 0.47 | 0.73 | |
Price to Tangible BV |
0.72 | 0.67 | 0.54 | 0.80 | |
EV/Sales |
1.13 | 1.05 | 0.74 | 1.53 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
25.85 | (4.05) | (2.62) | (4.85) | |
EV/FCF |
(66.01) | (3.26) | (2.08) | (3.97) | |
Quick Ratio |
0.87 | 4.49 | 3.83 | 4.95 | |
Current Ratio |
5.34 | 6.34 | 5.31 | 6.48 | |
Net Debt/EBITDA |
— | 8.82 | 9.36 | 8.20 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.29 | 0.28 | 0.27 | 0.27 | |
Operating CF/Net income |
(8.31) | 0.80 | (0.29) | 3.34 | |
Capex/Depreciation |
— | (0.56) | (1.02) | 1.05 | |
Interest Coverage |
(3,221.00) | (611.41) | (2,036.59) | (2,264.87) | |
Research and Development Expense of Revenue |
15.08% | 17.04% | 19.93% | 17.00% | |
Selling, General and Administrative Expense of Revenue |
42.44% | 49.68% | 56.10% | 63.15% | |
Intangible Assets out of Total Assets |
0.00 | 0.12 | 0.12 | 0.07 | |
Share Based Compensation of Revenue |
8.98% | 10.10% | 13.90% | 11.13% | |
Graham Net Nets |
0.48 | 0.63 | 0.75 | 0.55 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.03%) | (13.74%) | (15.03%) | (7.46%) | |
Free Cash Flow Yield |
(0.93%) | (18.06%) | (23.05%) | (15.36%) | |
Revenue per Share |
3.27 | 3.05 | 2.30 | 2.71 | |
Operating CF per Share |
3.95 | (0.85) | 0.23 | (2.54) | |
Capex per Share |
0.00 | (0.14) | (0.17) | (0.16) | |
Free Cash Flow per Share |
3.95 | (0.99) | 0.06 | (2.70) | |
Cash per Share |
0.00 | 9.18 | 8.95 | 10.92 | |
Shareholders Equity per Share |
35.60 | 35.56 | 33.81 | 35.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
35.60 | 35.56 | 33.81 | 35.96 | |
Free Cash Flow |
109.23 | (27.62) | 1.90 | (83.12) | |
Working Capital |
311.86 | 383.01 | 388.91 | 465.52 | |
Capital Expenditures |
— | (3.86) | (5.19) | (4.98) | |
Net Current Asset Value |
289.51 | 361.53 | 366.83 | 443.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.05 | 0.07 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
66.84 | 71.06 | 70.38 | 76.89 | |
Average Payables |
17.53 | 17.22 | 19.68 | 18.51 | |
Average Assets |
1,146.75 | 1,144.53 | 1,181.06 | 1,216.74 | |
Average Common Equity |
1,052.73 | 1,053.81 | 1,083.46 | 1,117.94 |
Columns are period end dates · fundamentals updated 5 Nov 2026